首页 >
法规速递
-
Document: Opinion of the CVMP on the establishment of maximum residue limits: Fluralaner ( EMEA/V/MRL/004380/EXTN/0002)-2026/3/6
2026-03-09查看详情 > -
Document: Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)-2026/3/6
2026-03-09查看详情 > -
Page: ICH E2D post-approval safety data management - scientific guideline-2026/3/6
2026-03-09查看详情 > -
Document: EU implementation strategy of ICH E2D(R1) Guideline - Post-approval safety data: Definitions and standards for management and reporting of individual case safety reports-2026/3/6
2026-03-09查看详情 > -
Document: Highlight report - Combination Products Operational Group (COMBO) - In Vitro Diagnostics stream - February 2026-2026/3/6
2026-03-09查看详情 > -
Document: Darwin EU: Making health data count-2026/3/6
2026-03-09查看详情 > -
Page: Orphan designation: Overview-2026/3/6
2026-03-09查看详情 > -
Page: Variations not requiring assessment (veterinary medicines)-2026/3/5
2026-03-06查看详情 > -
Page: Transferring a veterinary marketing authorisation-2026/3/5
2026-03-06查看详情 > -
Page: Pre-authorisation guidance under the Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6)-2026/3/5
2026-03-06查看详情 >
